DermAb.io’s cover photo
DermAb.io

DermAb.io

Biotechnology Research

Skin biomarker platform for precision medicine in treatment of chronic and autoimmune diseases

About us

DermAb.io is developing a clinical decision support system for prescribing personalized biologic therapies. Our non-invasive technology retrieves biomarkers painlessly from the skin’s surface. This tool provides the predictive value for physicians to prescribe the most effective biological medication right away. The trial and error method applied today can add a cost of $12,000 per patient, and extend the patient’s pain for months. The DermAb.io platform will significantly shorten the time to reach a proper treatment regimen, reducing payers’ costs and patients’ suffering. Women are disproportionately affected by autoimmune diseases. They tend to respond less to biologics and have more adverse events. This is the reason DermAb.io established in 2024 the @FEMMUNE initiative aiming to promote awareness of the sex and gender disparity in autoimmune diseases.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Haifa
Type
Partnership
Founded
2022

Locations

Employees at DermAb.io

Updates

Similar pages

Browse jobs